Fig. 2From: Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetesRandom effect meta-analysis of nine trials with five SGLT-21 (empagliflozin, canagliflozin, dapagliflozin, eurtugliflozin, sotagliflozin) on hospitalization for heart failure (HF) in patients with or without T2D, and with or without HF at baseline. Overall hazard ratio (HF) is 0.67 (95% Confidence Intervals 0.60–0.74)Back to article page